



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KLEIN Examiner: Unassigned
U.S.S.N.: 09/887,540 Group Art Unit: 1645
Filed: June 21, 2001 Docket: R-193
For: TRANSGENIC MICE CONTAINING LPR5 GENE DISRUPTIONS

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

MAR 08 2002

Sir:

TECH CENTER 1600/2900

Attached is a Form PTO-1449 listing each of the enclosed documents.

This Information Disclosure Statement (“IDS”) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is respectfully requested, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Should a first Office Action on the merits have been issued on the same day or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee under Rule 17(p) to our Deposit Account No. 50-1271, Order No. R-193 and proceed to consider this IDS.

Consideration of the foregoing and enclosures, the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column, and an action on the merits of this application are respectfully requested.

Respectfully submitted,
DELTAGEN, INC.

Date
740 Bay Road
Redwood City, CA 94063

Mariette A. Lapiz
Mariette A. Lapiz
Reg. No. 44,202
Phone: 650/569-5172

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformity and not considered. Include copy of this form with next communication to applicant.